bioAffinity Technologies, Inc.
NASDAQ Capital MarketTotal Valuation
bioAffinity Technologies, Inc. carries a market capitalization of 5.35M, placing it among publicly traded companies globally. Its enterprise value stands at 54.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.35M |
| Enterprise Value | 54.79M |
Share Statistics
bioAffinity Technologies, Inc. currently has 4.50M shares outstanding.
| Shares Outstanding | 4.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 10.10 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -5.30 |
| P/OCF Ratio | -5.30 |
Enterprise Valuation
| EV / Sales | 12.64 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
bioAffinity Technologies, Inc. maintains a current ratio of 7.62, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.36, indicating elevated leverage, while an interest coverage ratio of -263.94 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.62 |
| Quick Ratio | 7.03 |
| Debt / Equity | 61.36 |
| Debt / EBITDA | N/A |
| Interest Coverage | -263.94 |
Financial Efficiency
| Return on Equity (ROE) | -1,169.65 |
| Return on Assets (ROA) | -497.54 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 126.04 |
Taxes
| Income Tax | 6,363.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
bioAffinity Technologies, Inc.'s stock has declined approximately -88.1337% over the past 52 weeks. The 50-day moving average sits at 9.03, while the 200-day moving average is 22.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -88.1337% |
| 50-Day Moving Average | 9.03 |
| 200-Day Moving Average | 22.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, bioAffinity Technologies, Inc. generated 4.34M in revenue and converted that into -11.82M in net income, yielding earnings per share of -3.29. EBITDA reached -8.75M, while operating income came in at -9.10M.
| Revenue | 4.34M |
| Gross Profit | 1.57M |
| Operating Income | -9.10M |
| Pretax Income | -11.81M |
| Net Income | -11.82M |
| EBITDA | -8.75M |
| EBIT | -9.10M |
| Earnings Per Share (EPS) | -3.29 |
Cash Flow
bioAffinity Technologies, Inc. produced -8.27M in operating cash flow over the past twelve months. After subtracting -2,018.00 in capital expenditures, free cash flow totaled -8.27M - equivalent to -2.30 per share.
| Operating Cash Flow | -8.27M |
| Capital Expenditures | -2,018.00 |
| Free Cash Flow | -8.27M |
| FCF Per Share | -2.30 |
Margins
bioAffinity Technologies, Inc. operates with a gross margin of 36.10, reflecting its pricing power and cost economics. The operating margin of -209.87 and net profit margin of -272.56 provide insight into operational efficiency.
| Gross Margin | 36.10 |
| Operating Margin | -209.87 |
| Pretax Margin | -272.41 |
| Profit Margin | -272.56 |
| EBITDA Margin | -201.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -19.28 |
| FCF Yield | -18.87 |
Stock Splits
bioAffinity Technologies, Inc.'s most recent stock split took place on August 24, 2026 with a 15:1 split ratio.
| Last Split Date | 8/24/2026 |
| Split Ratio | 15:1 |
Scores
bioAffinity Technologies, Inc. posts an Altman Z-Score of 36.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 36.06 |